ABVX
ABIVAX SP ADS (ABVX)
NASDAQ
$136.43+$0.45 (+0.33%)
Price as of Jul 14, 2026 6:14 AM EDT
  • $11.9B
    Market Cap
  • 1,439.98%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
5.2M
-12.76%
6.0M
-7.42%
6.4M
N/A
Research and Development Expense
-177.8M
+21.31%
-146.5M
+42.02%
-103.2M
N/A
Depreciation and Amortization Expense
1.1M
-2.55%
1.1M
+55.59%
707,000
N/A
Total Operating Expenses
67.7M
+105.40%
32.9M
+47.15%
22.4M
N/A
Operating Profit
-246.1M
+42.24%
-173.0M
+35.81%
-127.4M
N/A
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
4.6M
-63.29%
12.4M
+169.40%
4.6M
N/A
Income before Taxes
-336.1M
+90.70%
-176.2M
+19.29%
-147.7M
N/A
Income Taxes
5.8M
N/A
0
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-336.1M
+90.70%
-176.2M
+19.29%
-147.7M
N/A
Net Income from Continuing Operations Applicable to Common
-336.1M
+90.70%
-176.2M
+19.29%
-147.7M
N/A
Basic EPS and Net Income
-4.83
+72.50%
-2.80
-18.37%
-3.43
N/A
Diluted EPS and Net Income
-4.83
+72.50%
-2.80
-18.37%
-3.43
N/A
Basic Weighted Average Shares
69.5M
+10.28%
63.0M
+46.39%
43.1M
N/A
Diluted Weighted Average Shares
69.5M
+10.28%
63.0M
+46.39%
43.1M
N/A
Balance Sheet
Cash and Cash Equivalents
516.7M
+258.26%
144.2M
-42.76%
251.9M
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
516.7M
+258.26%
144.2M
-42.76%
251.9M
N/A
Total Current Assets
551.2M
+222.99%
170.7M
-40.32%
286.0M
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
33.1M
-4.23%
34.6M
-15.90%
41.1M
N/A
Total Assets
584.3M
+184.73%
205.2M
-37.25%
327.1M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
63.0M
-32.96%
94.0M
+34.20%
70.0M
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
66.1M
-6.41%
70.6M
+15.80%
61.0M
N/A
Total Liabilities
30.8M
-55.42%
69.1M
+14.45%
60.3M
N/A
Retained Earnings
N/A
N/A
N/A
N/A
N/A
N/A
Total Stockholders Equity
455.2M
+1,021.64%
40.6M
-79.29%
196.0M
N/A
Total Shares Outstanding
N/A
N/A
63.3M
+0.68%
62.9M
N/A
Cash Flow
Cash from Operating Activities
-161.1M
+4.58%
-154.1M
+58.62%
-97.1M
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
-8.2M
-151.98%
15.8M
+294.71%
-8.1M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
547.3M
+1,840.32%
28.2M
-91.59%
335.3M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-85.14%
+28.56%
-66.22%
N/A
N/A
N/A
Return on Equity
-135.58%
-8.99%
-148.98%
N/A
N/A
N/A
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
8.75
+381.74%
1.82
N/A
N/A
N/A
Cash Ratio
8.20
+434.35%
1.53
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow